Diagnosis and treatment of glomerular diseases in elderly patients

Advances in Chronic Kidney Disease

Volumn 21, Issue 2, 2014, Pages 228-246

  Qian, Qi ^a   Nasr, Samih H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chronic kidney dysfunction; Diagnosis; Elderly patients; Glomerular diseases; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORAMBUCIL; CLEVIDIPINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESMOLOL; FENOLDOPAM; HYDRALAZINE; IBANDRONIC ACID; LABETALOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; NIMODIPINE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PHENTOLAMINE; RISEDRONIC ACID; SPIRONOLACTONE; TACROLIMUS; UNINDEXED DRUG; ZOLEDRONIC ACID;

AGED; AGING; BACTERIAL INFECTION; BREAST CANCER; CARDIOVASCULAR RISK; CLINICAL FEATURE; COGNITION; COMORBIDITY; DIABETIC NEPHROPATHY; FOCAL GLOMERULOSCLEROSIS; GERIATRIC DISORDER; GLOMERULONEPHRITIS; GLOMERULOPATHY; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY CANCER; KIDNEY DISEASE; KIDNEY ISCHEMIA; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; NONHUMAN; PARANEOPLASTIC SYNDROME; PATIENT PREFERENCE; PLASMA CELL DYSCRASIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENOVASCULAR DISEASE; REVIEW; STOMACH CARCINOMA; SYSTEMIC VASCULITIS; THYMOMA;

CHRONIC KIDNEY DYSFUNCTION; DIAGNOSIS; ELDERLY PATIENTS; GLOMERULAR DISEASES; TREATMENT;

AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ATHEROSCLEROSIS; DIABETIC NEPHROPATHIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; HYPERTENSION; ISCHEMIA; RENAL INSUFFICIENCY, CHRONIC;

EID: 84896893578     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.01.004     Document Type: Review

References (205)

1. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298(17):2038-2047.
2. Stevens L.A., Li S., Wang C., et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010, 55(3 suppl 2):S23-S33.
3. MMWR Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007, 56(08):161-165. Available at:, Accessed July 24, 2013. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5608a2.htm.
4. Abdelhafiz A.H., Brown S.H., Bello A., El Nahas M. Chronic kidney disease in older people: physiology, pathology or both?. Nephron Clin Pract 2010, 116(1):c19-c24.
5. Glassock R.J., Rule A.D. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int 2012, 82(3):270-277.
6. Anderson S., Brenner B.M. Effects of aging on the renal glomerulus. Am J Med 1986, 80(3):435-442.
7. Nyengaard J.R., Bendtsen T.F. Glomerular number and size in relation to age, kidney weight, and body surface in normal man. Anat Rec 1992, 232(2):194-201.
8. Davies D.F., Shock N.W. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950, 29(5):496-507.
9. Wills L.P., Schnellmann R.G. Telomeres and telomerase in renal health. J Am Soc Nephrol 2011, 22(1):39-41.
10. Palacios J.A., Herranz D., De Bonis M.L., Velasco S., Serrano M., Blasco M.A. SIRT1 contributes to telomere maintenance and augments global homologous recombination. J Cell Biol 2010, 191(7):1299-1313.
11. Doi S., Zou Y., Togao O., et al. Klotho inhibits transforming growthfactor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011, 286(10):8655-8665.
12. Chang J., Ma J.Z., Zeng Q., et al. Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK). Am J Physiol Renal Physiol 2013, 304(4):F348-F355.
13. Davison A.M., Johnston P.A. Glomerulonephritis in the elderly. Nephrol Dial Transplant 1996, 11(suppl 9):34-37.
14. Vendemia F., Gesualdo L., Schena F.P., D'Amico G. Epidemiology of primary glomerulonephritis in the elderly. Report from the Italian Registry of Renal Biopsy. J Nephrol 2001, 14(5):340-352.
15. Moutzouris D.A., Herlitz L., Appel G.B., et al. Renal biopsy in the very elderly. Clin J Am Soc Nephrol 2009, 4(6):1073-1082.
16. Parrish A.E. Complications of percutaneous renal biopsy: a review of 37 years' experience. Clin Nephrol 1992, 38(3):135-141.
17. Haas M., Spargo B.H., Wit E.J., Meehan S.M. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 2000, 35(3):433-447.
18. Nair R., Bell J.M., Walker P.D. Renal biopsy in patients aged 80 years and older. Am J Kidney Dis 2004, 44(4):618-626.
19. Hanko J.B., Mullan R.N., O'Rourke D.M., McNamee P.T., Maxwell A.P., Courtney A.E. The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant 2009, 24(10):3050-3054.
20. Verde E., Quiroga B., Rivera F., Lopez-Gomez J.M. Renal biopsy in very elderly patients: data from the Spanish Registry of Glomerulonephritis. Am J Nephrol 2012, 35(3):230-237.
21. Mangoni A.A., Jackson S.H. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004, 57(1):6-14.
22. Shi S., Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab 2011, 12(7):601-610.
23. Collins A.J., Foley R.N., Chavers B., et al. United States Renal Data System 2011 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States. Am J Kidney Dis 2012, 59(1 suppl 1):A7. e1-e420.
24. Kan W.C., Wang J.J., Wang S.Y., et al. The new comorbidity index for predicting survival in elderly dialysis patients: a long-term population-based study. PLoS One 2013, 8(8):e68748.
25. Liu J., Huang Z., Gilbertson D.T., Foley R.N., Collins A.J. An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 2010, 77(2):141-151.
26. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365(9455):217-223.
27. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
28. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002, 106(24):3068-3072.
29. National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. National High Blood Pressure Education Program Working Group. Hypertension 1994, 23(3):275-285.
30. Chiong J.R., Aronow W.S., Khan I.A., et al. Secondary hypertension: current diagnosis and treatment. Int J Cardiol 2008, 124(1):6-21.
31. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157(21):2413-2446.
32. Aronow W.S., Ahn C., Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci 2002, 57(1):M45-M46.
33. Lloyd-Jones D.M., Evans J.C., Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005, 294(4):466-472.
34. Lakatta E.G. Mechanisms of hypertension in the elderly. J Am Geriatr Soc 1989, 37(8):780-790.
35. Dao H.H., Essalihi R., Bouvet C., Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res 2005, 66(2):307-317.
36. Virdis A., Bruno R.M., Neves M.F., Bernini G., Taddei S., Ghiadoni L. Hypertension in the elderly: an evidence-based review. Curr Pharm Des 2011, 17(28):3020-3031.
37. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117(25):e510-e526.
38. Oliveras A., de la Sierra A. Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens 29 August 2013, 1-5. Available at:, Accessed January 29, 2014. http://dx.doi.org/10.1038/jhh.2013.77.
39. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358(18):1887-1898.
40. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991, 265(24):3255-3264.
41. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350(9080):757-764.
42. Staessen J.A., Gasowski J., Wang J.G., et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355(9207):865-872.
43. Wang J.G., Liu G., Wang X., et al. Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J Hum Hypertens 1996, 10(11):735-742.
44. Tuncel M., Ram V.C. Hypertensive emergencies. Etiology and management. Am J Cardiovasc Drugs 2003, 3(1):21-31.
45. Wallach R., Karp R.B., Reves J.G., Oparil S., Smith L.R., James T.N. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol 1980, 46(4):559-565.
46. Kincaid-Smith P. Malignant hypertension. J Hypertens 1991, 9(10):893-899.
47. Rodriguez M.A., Kumar S.K., De Caro M. Hypertensive crisis. Cardiol Rev 2010, 18(2):102-107.
48. van den Born B.J., van der Hoeven N.V., Groot E., et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension 2008, 51(4):862-866.
49. Pergolini M.S. The management of hypertensive crises: a clinical review. Clin Ter 2009, 160(2):151-157.
50. Khanna A., McCullough P.A. Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure. Rev Cardiovasc Med 2003, 4(4):255-259.
51. Deshmukh A., Kumar G., Kumar N., et al. Effect of Joint National Committee VII report on hospitalizations for hypertensive emergencies in the United States. Am J Cardiol 2011, 108(9):1277-1282.
52. Piecha G., Wiecek A., Januszewicz A. Epidemiology and optimal management in patients with renal artery stenosis. J Nephrol 2012, 25(6):872-878.
53. Fatica R.A., Port F.K., Young E.W. Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis 2001, 37(6):1184-1190.
54. Hansen K.J., Edwards M.S., Craven T.E., et al. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg 2002, 36(3):443-451.
55. Khosla S., Kunjummen B., Manda R., et al. Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography. Catheter Cardiovasc Interv 2003, 58(3):400-403.
56. MacDowall P., Kalra P.A., O'Donoghue D.J., Waldek S., Mamtora H., Brown K. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet 1998, 352(9121):13-16.
57. Olin J.W., Melia M., Young J.R., Graor R.A., Risius B. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 1990, 88(1N):46N-51N.
58. Pearce J.D., Craven B.L., Craven T.E., et al. Progression of atherosclerotic renovascular disease: a prospective population-based study. JVasc Surg 2006, 44(5):955-962. discussion 962-963.
59. Scoble J.E., Maher E.R., Hamilton G., Dick R., Sweny P., Moorhead J.F. Atherosclerotic renovascular disease causing renal impairment-a case for treatment. Clin Nephrol 1989, 31(3):119-122.
60. Appel R.G., Bleyer A.J., Reavis S., Hansen K.J. Renovascular disease in older patients beginning renal replacement therapy. Kidney Int 1995, 48(1):171-176.
61. van Ampting J.M., Penne E.L., Beek F.J., Koomans H.A., Boer W.H., Beutler J.J. Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 2003, 18(6):1147-1151.
62. Harding M.B., Smith L.R., Himmelstein S.I., et al. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 1992, 2(11):1608-1616.
63. Kuroda S., Nishida N., Uzu T., et al. Prevalence of renal artery stenosis in autopsy patients with stroke. Stroke 2000, 31(1):61-65.
64. Kalra P.A., Guo H., Kausz A.T., et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int 2005, 68(1):293-301.
65. Conlon P.J., Athirakul K., Kovalik E., et al. Survival in renal vascular disease. J Am Soc Nephrol 1998, 9(2):252-256.
66. Conlon P.J., Little M.A., Pieper K., Mark D.B. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int 2001, 60(4):1490-1497.
67. Johansson M., Herlitz H., Jensen G., Rundqvist B., Friberg P. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. J Hypertens 1999, 17(12 pt 1):1743-1750.
68. Reid I.A. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992, 262(6 pt 1):E763-E778.
69. Adamczak M., Wiecek A. Ischemic nephropathy-pathogenesis and treatment. Nefrologia 2012, 32(4):432-438.
70. Eirin A., Zhang X., Zhu X.Y., et al. Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis. Nephrol Dial Transplant 2013, 1-9.
71. Eirin A., Gloviczki M.L., Tang H., et al. Inflammatory and injury signals released from the post-stenotic human kidney. Eur Heart J 2013, 34(7):540-548a.
72. Saad A., Herrmann S.M., Crane J., et al. Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate. Circ Cardiovasc Interv 2013, 6(4):428-435.
73. Keddis M.T., Garovic V.D., Bailey K.R., Wood C.M., Raissian Y., Grande J.P. Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. Nephrol Dial Transplant 2010, 25(11):3615-3622.
74. Schreiber M.J., Pohl M.A., Novick A.C. The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am 1984, 11(3):383-392.
75. Shanley P.F. The pathology of chronic renal ischemia. Semin Nephrol 1996, 16(1):21-32.
76. Textor S.C., Lerman L.O. Renal artery stenosis: medical versus interventional therapy. Curr Cardiol Rep 2013, 15(10):409.
77. Sarkodieh J.E., Walden S.H., Low D. Imaging and management ofatherosclerotic renal artery stenosis. Clin Radiol 2013, 68(6):627-635.
78. Chrysochou C., Mendichovszky I.A., Buckley D.L., Cheung C.M., Jackson A., Kalra P.A. BOLD imaging: a potential predictive biomarker of renal functional outcome following revascularization in atheromatous renovascular disease. Nephrol Dial Transplant 2012, 27(3):1013-1019.
79. Jafar T.H., Stark P.C., Schmid C.H., et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60(3):1131-1140.
80. Hackam D.G., Spence J.D., Garg A.X., Textor S.C. Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension 2007, 50(6):998-1003.
81. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377(9784):2181-2192.
82. Bax L., Woittiez A.J., Kouwenberg H.J., et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009, 150(12):840-848.
83. Wheatley K., Ives N., Gray R., et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009, 361(20):1953-1962.
84. Murphy T.P., Cooper C.J., Dworkin L.D., et al. The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study: rationale and methods. J Vasc Interv Radiol 2005, 16(10):1295-1300.
85. Collins A.J., Foley R.N., Herzog C., et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 2010, 55(1 suppl 1):S1-S420. A6-A7.
86. Ginter E., Simko V. Global prevalence and future of diabetes mellitus. Adv Exp Med Biol 2012, 771:35-41.
87. Sloan F.A., Bethel M.A., Ruiz D., Shea A.M., Feinglos M.N. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med 2008, 168(2):192-199. discussion 199.
88. Cowie C.C., Rust K.F., Ford E.S., et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32(2):287-294.
89. Sue Kirkman M., Briscoe V.J., Clark N., et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc 2012, 60(12):2342-2356.
90. Boyle J.P., Thompson T.J., Gregg E.W., Barker L.E., Williamson D.F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010, 8:29.
91. Rosner M., Abdel-Rahman E., Williams M.E. Geriatric nephrology: responding to a growing challenge. Clin J Am Soc Nephrol 2010, 5(5):936-942.
92. Mei C., Zheng F. Chronic inflammation potentiates kidney aging. Semin Nephrol 2009, 29(6):555-568.
93. Kasper M., Funk R.H. Age-related changes in cells and tissues due to advanced glycation end products (AGEs). Arch Gerontol Geriatr 2001, 32(3):233-243.
94. Singh I., Marshall M.C. Diabetes mellitus in the elderly. Endocrinol Metab Clin North Am 1995, 24(2):255-272.
95. de Zeeuw D., Remuzzi G., Parving H.H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110(8):921-927.
96. Blickle J.F., Doucet J., Krummel T., Hannedouche T. Diabetic nephropathy in the elderly. Diabetes Metab 2007, 33(suppl 1):S40-S55.
97. Markowitz G.S., Lin J., Valeri A.M., Avila C., Nasr S.H., D'Agati V.D. Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol 2002, 33(8):826-835.
98. Nasr S.H., D'Agati V.D. Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol 2007, 18(7):2032-2036.
99. Sharma S.G., Bomback A.S., Radhakrishnan J., et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 2013, 8(10):1718-1724.
100. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. JHypertens 1993, 11(3):309-317.
101. Brown A.F., Mangione C.M., Saliba D., Sarkisian C.A. Guidelines for improving the care of the older person with diabetes mellitus. JAm Geriatr Soc 2003, 51(5 suppl guidelines):S265-S280.
102. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345(12):861-869.
103. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345(12):851-860.
104. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358(23):2433-2446.
105. Joss N., Ferguson C., Brown C., Deighan C.J., Paterson K.R., Boulton-Jones J.M. Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 2004, 97(4):219-227.
106. Watts R.A., Lane S.E., Bentham G., Scott D.G. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000, 43(2):414-419.
107. Andrews M., Edmunds M., Campbell A., Walls J., Feehally J. Systemic vasculitis in the 1980s-is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis?. J R Coll Physicians Lond 1990, 24(4):284-288.
108. Yashiro M., Muso E., Itoh-Ihara T., et al. Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). Am J Kidney Dis 2000, 35(5):889-895.
109. Gregorini G., Ferioli A., Donato F., et al. Association between silica exposure and necrotizing crescentic glomerulonephritis with p-ANCA and anti-MPO antibodies: a hospital-based case-control study. Adv Exp Med Biol 1993, 336:435-440.
110. Nuyts G.D., Van Vlem E., De Vos A., et al. Wegener granulomatosis is associated to exposure to silicon compounds: a case-control study. Nephrol Dial Transplant 1995, 10(7):1162-1165.
111. Hogan S.L., Satterly K.K., Dooley M.A., Nachman P.H., Jennette J.C., Falk R.J. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol 2001, 12(1):134-142.
112. Duna G.F., Cotch M.F., Galperin C., Hoffman D.B., Hoffman G.S. Wegener's granulomatosis: role of environmental exposures. Clin Exp Rheumatol 1998, 16(6):669-674.
113. Raynauld J.P., Bloch D.A., Fries J.F. Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis. J Rheumatol 1993, 20(9):1524-1526.
114. Choi H.K., Merkel P.A., Walker A.M., Niles J.L. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000, 43(2):405-413.
115. Krafcik S.S., Covin R.B., Lynch J.P., Sitrin R.G. Wegener's granulomatosis in the elderly. Chest 1996, 109(2):430-437.
116. Hogan S.L., Nachman P.H., Wilkman A.S., Jennette J.C., Falk R.J. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7(1):23-32.
117. Hoganson D.D., From A.M., Michet C.J. ANCA vasculitis in the elderly. J Clin Rheumatol 2008, 14(2):78-81.
118. Bomback A.S., Appel G.B., Radhakrishnan J., et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int 2011, 79(7):757-764.
119. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL. Clin Exp Immunol 1995, 101(suppl 1):29-34.
120. Szpirt W.M., Heaf J.G., Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis-a clinical randomized controlled trial. Nephrol Dial Transplant 2011, 26(1):206-213.
121. Jones R.B., Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363(3):211-220.
122. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232.
123. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
124. Leung N., Bridoux F., Hutchison C.A., et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012, 120(22):4292-4295.
125. Palumbo A., Bringhen S., Ludwig H., et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011, 118(17):4519-4529.
126. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 354(13):1362-1369.
127. Nasr S.H., Valeri A.M., Sethi S., et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis 2012, 59(6):786-794.
128. Nasr S.H., Said S.M., Valeri A.M., et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int 2013, 83(3):463-470.
129. Said S.M., Sethi S., Valeri A.M., et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 2013, 8(9):1515-1523.
130. Gertz M.A., Leung N., Lacy M.Q., et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 2009, 24(10):3132-3137.
131. Murphy C.L., Wang S., Kestler D., et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis 2010, 56(6):1100-1107.
132. Leung N., Nasr S.H., Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood 2012, 120(16):3206-3213.
133. Sethi S., Vrana J.A., Theis J.D., et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 2012, 82(2):226-234.
134. Nasr S.H., Valeri A.M., Cornell L.D., et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012, 7(2):231-239.
135. Nasr S.H., Satoskar A., Markowitz G.S., et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009, 20(9):2055-2064.
136. Nasr S.H., Fidler M.E., Cornell L.D., et al. Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrol Dial Transplant 2012, 27(11):4137-4146.
137. Nasr S.H., Markowitz G.S., Reddy B.S., Maesaka J., Swidler M.A., D'Agati V.D. Dysproteinemia, proteinuria, and glomerulonephritis. Kidney Int 2006, 69(4):772-775.
138. Zand L., Kattah A., Fervenza F.C., et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis 2013, 62(3):506-514.
139. Sethi S., Zand L., Leung N., et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010, 5(5):770-782.
140. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007, 357(11):1083-1093.
141. Muta T., Miyamoto T., Fujisaki T., et al. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Intern Med 2013, 52(1):63-70.
142. Nasr S.H., Markowitz G.S., Stokes M.B., Said S.M., Valeri A.M., D'Agati V.D. Acute postinfectious glomerulonephritis in the modern era: experience with 86 adults and review of the literature. Medicine (Baltimore) 2008, 87(1):21-32.
143. Montseny J.J., Meyrier A., Kleinknecht D., Callard P. The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature. Medicine (Baltimore) 1995, 74(2):63-73.
144. Nasr S.H., Fidler M.E., Valeri A.M., et al. Postinfectious glomerulonephritis in the elderly. J Am Soc Nephrol 2011, 22(1):187-195.
145. Nasr S.H., D'Agati V.D. IgA-dominant postinfectious glomerulonephritis: a new twist on an old disease. Nephron Clin Pract 2011, 119(1):c18-c25. discussion c26.
146. Nasr S.H., Markowitz G.S., Whelan J.D., et al. IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy. Hum Pathol 2003, 34(12):1235-1241.
147. Nasr S.H., Radhakrishnan J., D'Agati V.D. Bacterial infection-related glomerulonephritis in adults. Kidney Int 2013, 83(5):792-803.
148. Lefaucheur C., Stengel B., Nochy D., et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 2006, 70(8):1510-1517.
149. Beck L.H. Membranous nephropathy and malignancy. Semin Nephrol 2010, 30(6):635-644.
150. Beck L.H., Bonegio R.G., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361(1):11-21.
151. Larsen C.P., Messias N.C., Silva F.G., Messias E., Walker P.D. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 2013, 26(5):709-715.
152. Bjorneklett R., Vikse B.E., Svarstad E., et al. Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 2007, 50(3):396-403.
153. Mallouk A., Pham P.T., Pham P.C. Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol 2006, 10(4):284-289.
154. Zurada J.M., Ward K.M., Grossman M.E. Henoch-Schonlein purpura associated with malignancy in adults. J Am Acad Dermatol 2006, 55(suppl 5):S65-S70.
155. Mustonen J., Pasternack A., Helin H. IgA mesangial nephropathy in neoplastic diseases. Contrib Nephrol 1984, 40:283-291.
156. Werner T.L., Agarwal N., Carney H.M., Rodgers G.M. Management of cancer-associated thrombotic microangiopathy: what is the right approach?. Am J Hematol 2007, 82(4):295-298.
157. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs-nice or necessary?. Rev Gastroenterol Disord 2004, 4(suppl 4):S33-S41.
158. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med 2001, 110(1A):4S-7S.
159. Thomas J., Straus W.L., Bloom B.S. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am J Gastroenterol 2002, 97(9):2215-2219.
160. Radford M.G., Holley K.E., Grande J.P., et al. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996, 276(6):466-469.
161. Mihovilovic K., Ljubanovic D., Knotek M. Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs. Clin Drug Investig 2011, 31(5):351-355.
162. Qin W., Beck L.H., Zeng C., et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011, 22(6):1137-1143.
163. Huerta C., Castellsague J., Varas-Lorenzo C., Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005, 45(3):531-539.
164. Harley C., Wagner S. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Clin Ther 2003, 25(1):139-149.
165. Clive D.M., Stoff J.S. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984, 310(9):563-572.
166. Markowitz G.S., Appel G.B., Fine P.L., et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001, 12(6):1164-1172.
167. Hiroi-Furuya E., Kameda T., Hiura K., et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int 1999, 64(3):219-223.
168. Barri Y.M., Munshi N.C., Sukumalchantra S., et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004, 65(2):634-641.
169. Kyle R.A., Yee G.C., Somerfield M.R., et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007, 25(17):2464-2472.
170. Markowitz G.S., Nasr S.H., Stokes M.B., D'Agati V.D. Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010, 5(4):607-615.
171. Edwards C., House A., Shahinian V., Knoll G. Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy. Nephrol Dial Transplant 2002, 17(8):1524-1526.
172. Said T., Al-Otaibi T., Al-Wahaib S., et al. Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience. Transplant Proc 2010, 42(3):814-816.
173. Zech P., Colon S., Pointet P., Deteix P., Labeeuw M., Leitienne P. The nephrotic syndrome in adults aged over 60: etiology, evolution and treatment of 76 cases. Clin Nephrol 1982, 17(5):232-236.
174. Haas M., Meehan S.M., Karrison T.G., Spargo B.H. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997, 30(5):621-631.
175. Kitiyakara C., Eggers P., Kopp J.B. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004, 44(5):815-825.
176. Dragovic D., Rosenstock J.L., Wahl S.J., Panagopoulos G., DeVita M.V., Michelis M.F. Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns. Clin Nephrol 2005, 63(1):1-7.
177. Ferro G., Dattolo P., Nigrelli S., Michelassi S., Pizzarelli F. Clinical pathological correlates of renal biopsy in elderly patients. Clin Nephrol 2006, 65(4):243-247.
178. Cameron J.S. Nephrotic syndrome in the elderly. Semin Nephrol 1996, 16(4):319-329.
179. O'Callaghan C.A., Hicks J., Doll H., Sacks S.H., Cameron J.S. Characteristics and outcome of membranous nephropathy in older patients. Int Urol Nephrol 2002, 33(1):157-165.
180. Passerini P., Como G., Vigano E., et al. Idiopathic membranous nephropathy in the elderly. Nephrol Dial Transplant 1993, 8(12):1321-1325.
181. Zent R., Nagai R., Cattran D.C. Idiopathic membranous nephropathy in the elderly: a comparative study. Am J Kidney Dis 1997, 29(2):200-206.
182. Ponticelli C., Zucchelli P., Passerini P., et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989, 320(1):8-13.
183. Bizzarri D., Imperiali P., Duranti E., Sasdelli M. Idiopathic membranous glomerulonephritis in the elderly. Contrib Nephrol 1993, 105:65-70.
184. Mycophenolate mofetil in membranous nephropathy: A prospective cohort study (abstract). JASN 2005, 16:531A.
185. Ishimoto T., Shimada M., Araya C.E., Huskey J., Garin E.H., Johnson R.J. Minimal change disease: a CD80 podocytopathy?. Semin Nephrol 2011, 31(4):320-325.
186. Chugh S.S., Clement L.C., Mace C. New insights into human minimal change disease: lessons from animal models. Am J Kidney Dis 2012, 59(2):284-292.
187. Shimizu M., Khoshnoodi J., Akimoto Y., et al. Expression of galectin-1, a new component of slit diaphragm, is altered in minimal change nephrotic syndrome. Lab Invest 2009, 89(2):178-195.
188. Jennette J.C., Falk R.J. Adult minimal change glomerulopathy with acute renal failure. Am J Kidney Dis 1990, 16(5):432-437.
189. Waldman M., Crew R.J., Valeri A., et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007, 2(3):445-453.
190. Korbet S.M., Schwartz M.M., Lewis E.J. Minimal-change glomerulopathy of adulthood. Am J Nephrol 1988, 8(4):291-297.
191. Nolasco F., Cameron J.S., Heywood E.F., Hicks J., Ogg C., Williams D.G. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int 1986, 29(6):1215-1223.
192. Nakayama M., Katafuchi R., Yanase T., Ikeda K., Tanaka H., Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002, 39(3):503-512.
193. KDIGO KDIGO Clinical Practice Guidelines for glomerulonephritis. Kidney Int Suppl 2012, 2:163-180.
194. Munyentwali H., Bouachi K., Audard V., et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013, 83(3):511-516.
195. Kitiyakara C., Kopp J.B., Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol 2003, 23(2):172-182.
196. Chou Y.H., Lien Y.C., Hu F.C., et al. Clinical outcomes and predictors for ESRD and mortality in primary GN. Clin J Am Soc Nephrol 2012, 7(9):1401-1408.
197. Hotta O., Yusa N., Furuta T., Onodera S., Kitamura H., Taguma Y. Membranoproliferative glomerulonephritis in the aged and its possible causal relationship with CD8+CD57+ lymphocytes. Clin Nephrol 1998, 49(3):138-144.
198. Wen Y.K., Chen M.L. Differences in new-onset IgA nephropathy between young adults and the elderly. Ren Fail 2010, 32(3):343-348.
199. Heras M., Saiz A., Pardo J., Fernandez-Reyes M.J., Sanchez R., Alvarez-Ude F. Nefrologia 2011, 31(2):234-236.
200. Cheng J., Zhang W., Zhang X.H., He Q., Tao X.J., Chen J.H. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract 2009, 63(6):880-888.
201. Li P.K., Kwan B.C., Chow K.M., Leung C.B., Szeto C.C. Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor. Am J Med 2013, 126(2):162-168.
202. Wilson C.B., Dixon F.J. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973, 3(2):74-89.
203. Cui Z., Zhao J., Jia X.Y., Zhu S.N., Zhao M.H. Clinical features and outcomes of anti-glomerular basement membrane disease in older patients. Am J Kidney Dis 2011, 57(4):575-582.
204. Levy J.B., Turner A.N., Rees A.J., Pusey C.D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001, 134(11):1033-1042.
205. Trends in aging-United States and worldwide. MMWR Morb Mortal Wkly Rep 2003, 52(6):101-104. 106.